|
CDC clinical stage: C, N (%)
|
324 (27.8)
|
300 (28.9)
|
24 (19.2)
|
|
Years since HIV diagnosis, median (IQR)
|
18 (13-20)
|
18 (13-20)
|
18 (14-21)
|
|
HIV transmission category, N (%)
| | | |
|
Intravenous drug use
|
724 (62.0)
|
651 (62.5)
|
73 (57.9)
|
|
Sexual
|
318 (27.2)
|
282 (27.1)
|
36 (28.6)
|
|
Transfusion
|
85 (7.3)
|
73 (7.0)
|
12 (9.5)
|
|
Other or unknown
|
40 (3.4)
|
35 (3.4)
|
5 (4.0)
|
|
Nadir CD4 (/μl), median (IQR)
|
150 (66-248)
|
146 (65-247)
|
169 (96-251)
|
|
CD4 cells count at initiation of antiretroviral treatment (/μl), median (IQR)
|
242 (139-357)
|
240 (132-354)
|
256 (191-396)
|
|
CD4 cells count at baseline (/μl), median (IQR)
|
442 (304-633)
|
438 (300-630)
|
492 (345-662)
|
|
CD4 cells count at baseline (/μl), N (%)
| | | |
|
<200
|
130 (11.2)
|
126 (12.2)
|
4 (3.1)
|
|
200-350
|
251 (21.6)
|
223 (21.6)
|
28 (22.0)
|
|
351-500
|
301 (25.9)
|
269 (26.1)
|
32 (25.2)
|
|
>500
|
479 (41.3)
|
416 (40.2)
|
63 (49.6)
|
|
Patients with <40 HIV RNA copies/ml, N (%)
|
797 (68.8)
|
702 (68.1)
|
95 (74.8)
|
|
Patients receiving HAART, N (%)
|
841 (71.6)
|
750 (71.6)
|
91 (71.6)
|
|
2 NRTI + 1 PI
|
613 (52.2)
|
552 (52.7)
|
61 (48.0)
|
|
2 NRTI + 1 NNRTI
|
183 (15.6)
|
158 (15.1)
|
25 (19.7)
|
|
1 NRTI + 1 NNRTI + 1 PI
|
45 (3.8)
|
40 (3.8)
|
5 (3.9)
|
|
Regimen including raltegravir
|
26 (2.2)
|
23 (2.2)
|
3 (2.4)
|
